Develops gene expression profile tests for skin cancers and esophageal diseases.
Jun 2026Revenue $357M/yrExpenses $389M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year
When will Castle Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $357M and expenses $389M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $344M | $387M | −$42.8M |
| Dec 2024 | $332M | $323M | $8.67M |
| Dec 2023 | $220M | $288M | −$68.0M |
| Dec 2022 | $137M | $210M | −$72.9M |
| Dec 2021 | $94.1M | $134M | −$40.1M |
| Dec 2020 | $62.6M | $69.2M | −$6.54M |
| Dec 2019 | $51.9M | $44.5M | $7.33M |
| Dec 2018 | $22.8M | $26.6M | −$3.84M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.